Pheochromocytoma: Difference between revisions

Jump to navigation Jump to search
Line 23: Line 23:
==[[Pheochromocytoma causes|Causes of Pheochromocytoma]]==
==[[Pheochromocytoma causes|Causes of Pheochromocytoma]]==
==[[Pheochromocytoma history and symptoms|History & Symptoms]]==
==[[Pheochromocytoma history and symptoms|History & Symptoms]]==
The [[signs]] and [[symptoms]] of a pheochromocytoma are those of [[sympathetic nervous system]] [[hyperactivity]], including:
*[[Elevated heart rate]]
*[[Elevated blood pressure]], including paroxysmal (sporadic, episodic) high blood pressure, which sometimes can be more difficult to detect; another clue to the presence of pheochromocytoma is [[orthostatic hypotension]] (a fall in [[systolic blood pressure]] greater than 20 [[mmHg]] or a fall in [[diastolic blood pressure]] greater than 10 [[mmHg]] on making the patient stand)
*[[Palpitations]]
*[[Anxiety]] often resembling that of a [[panic attack]]
*[[Diaphoresis]]
*[[Headaches]]
*[[Pallor]]
*[[Weight loss]]
*Localized [[amyloid]] deposits found microscopically
*Elevated blood glucose level (due primarily to catecholamine stimulation of [[lipolysis]] (breakdown of stored fat) leading to high levels of [[free fatty acids]] and the subsequent inhibition of glucose uptake by muscle cells. Further, stimulation of beta-adrenergic receptors leads to glycogenolysis and gluconeogenesis and thus elevation of blood glucose levels).
A pheochromocytoma can also cause resistant [[arterial hypertension]]. A pheochromocytoma can be fatal if it causes [[malignant hypertension]], or severely [[high blood pressure]]. This hypertension is not well controlled with standard blood pressure medications.
Not all patients experience all of the signs and symptoms listed. The most common presentation is headache, excessive sweating, and increased heart rate, with the attack subsiding in less than one hour.
Tumors may grow very large, but most are smaller than 10 cm.


==Tumor Location==
==Tumor Location==

Revision as of 12:26, 21 January 2012

Pheochromocytoma
Micrograph of a pheochromocytoma.
ICD-10 C74.1
ICD-9 255.6
ICD-O: Template:ICDO
OMIM 171300
DiseasesDB 9912
MeSH D010673

Pheochromocytoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pheochromocytoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pheochromocytoma On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pheochromocytoma

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pheochromocytoma

CDC on Pheochromocytoma

Pheochromocytoma in the news

Blogs on Pheochromocytoma

Directions to Hospitals Treating Pheochromocytoma

Risk calculators and risk factors for Pheochromocytoma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Differentiating Pheochromocytoma from other Diseases

Causes of Pheochromocytoma

History & Symptoms

Tumor Location

In adults, 90% tumors are located unilaterally and are solitary, and 10% are located outside the adrenal gland. In children 50% are adrenal, while 25% are bilateral and 25% are extraadrenal. The common extradrenal locations are the abdomen, thorax and urinary bladder.

Diagnosis

Histopathology of adrenal pheochromocytoma. Adrenectomy specimen.
Epinephrine
Norepinephrine

The diagnosis can be established by measuring catecholamines and metanephrines in plasma or through a 24-hour urine collection. Care should be taken to rule out other causes of adrenergic (adrenalin-like) excess like hypoglycemia, stress, exercise, and drugs affecting the catecholamines like stimulants, methyldopa, dopamine agonists, or ganglion blocking antihypertensives. Various foodstuffs (e.g. vanilla ice cream) can also affect the levels of urinary metanephrine and VMA (vanillyl mandelic acid). Imaging by computed tomography or a T2 weighted MRI of the head, neck, and chest, and abdomen can help localize the tumor. Tumors can also be located using Iodine-131 meta-iodobenzylguanidine (I131 MIBG) imaging.

One diagnostic test used in the past for a pheochromocytoma is to administer clonidine, a centrally-acting alpha-2 agonist used to treat high blood pressure. Clonidine mimics catecholamines in the brain, causing it to reduce the activity of the sympathetic nerves controlling the adrenal medulla. A healthy adrenal medulla will respond to the Clonidine suppression test by reducing catecholamine production; the lack of a response is evidence of pheochromocytoma.

Another test is for the clinician to press gently on the adrenal gland. A pheochromocytoma will often release a burst of catecholamines, with the associated signs and symptoms quickly following. This method is not recommended because of possible complications arising from a potentially massive release of catecholamines.

Pheochromocytomas occur most often during young-adult to mid-adult life. Less than 10% of pheochromocytomas are malignant (cancerous), bilateral or pediatric.

These tumors can form a pattern with other endocrine gland cancers which is labeled multiple endocrine neoplasia (MEN). Pheochromocytoma may occur in patients with MEN 2 and MEN 3. VHL (Von Hippel Lindau) patients may also develop these tumors.

Patients experiencing symptoms associated with pheochromocytoma should be aware that it is rare. However, it often goes undiagnosed until autopsy; therefore patients might wisely choose to take steps to provide a physician with important clues, such as recording whether blood pressure changes significantly during episodes of apparent anxiety.

Medical Therapy

Surgical resection of the tumor is the treatment of first choice. Given the complexity of perioperative management, and the potential for catastrophic intra and postoperative complications, such surgery should be performed only at centers experienced in the area. In addition to the surgical expertise that such centers can provide, they will also have the necessary endocrine and anesthesia resources as well. It may also be nescessary to carry out adrenalectomy, a complete surgical removal of the affected adrenal gland(s).

Either surgical option requires prior treatment with both the non-specific alpha adrenoceptor blocker Phenoxybenzamine to counteract hypertension and the beta-1 adrenoceptor antagonist Atenolol to reduce cardiac output. Given before surgery, these can also block the effect of a sudden release of adrenaline during tumour removal, which would otherwise endanger the anaethetised patient.

Historical perspective

In 1886, Fränkel made the first description of a patient with pheochromocytoma, however the term was first coined by Pick, a pathologist, in 1912. In 1926, Roux (in Switzerland) and Mayo (in U.S.A.) were the first surgeons to remove pheochromocytomas.
Jaroszewski DE, Tessier DJ, Schlinkert RT, et al. Laparoscopic adrenalectomy for pheochromocytoma. Mayo Clin Proc. 2003; 78: 1501-1504.

Additional images

References

External links

Template:Epithelial neoplasms Template:SIB de:Phäochromozytom it:Feocromocitoma he:פאוכרומוציטומה nl:Feochromocytoom sv:Feokromocytom


Template:WikiDoc Sources